Claims
- 1. A compound of formula I, ##STR133## wherein--X represents (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene;
- n represents 1 or 2;
- Ar.sup.1 represents indanyl, naphthyl or phenyl, which latter two groups may be substituted by one or more substituents selected from the group consisting of chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), pyridyl, thiazinyl, phenyl and C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18 ;
- m represents an integer 1 to 3;
- R.sup.1, R.sup.2 and R.sup.3 independently represent H, C.sub.1-10 alkyl (optionally substituted by one or more fluorine atoms), C.sub.7-9 alkylphenyl or phenyl, which latter group is optionally substituted by hydroxy; and
- R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 independently represent H, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms) or phenyl;
- in which any alkyl group present may be interrupted by one or more oxygen atoms;
- provided that when X represents CH.sub.2 CH.sub.2, Ar.sup.1 may not represent phenyl or phenyl substituted with one or more substituents OR.sup.1, in which R.sup.1 represents C.sub.1-10 alkyl;
- or a pharmaceutically acceptable derivative thereof.
- 2. A compound of formula I as defined in claim 1, wherein X represents CH.sub.2 O, CH.sub.2 S or C.sub.2 alkylene and Ar.sup.1 represents--
- naphthyl, which may be substituted by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, and C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms); or
- biphenylyl, which may be substituted on the ring adjacent to X by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21 and C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), and on the ring remote from X by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5 C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18 ;
- or a pharmaceutically acceptable derivative thereof.
- 3. A pharmaceutical formulation including a compound of formula I as defined in claim 1 or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 4. A method of treatment of a reversible obstructive airways disease which comprises administering a therapeutically effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable derivative thereof, to a person suffering from, or susceptible to, such a disease.
- 5. A method as claimed in claim 4, wherein the disease is asthma.
- 6. A process for the preparation of compounds of formula I as defined in claim 1 which comprises:
- (a) reduction of a corresponding compound of formula II, ##STR134## wherein X.sup.a represents (CH.sub.2).sub.n S, (CH.sub.2).sub.n O or C.sub.2 alkylene and Ar.sup.1 is as defined in claim 1;
- (b) preparation of a compound of formula I, wherein X represents CH.sub.2 S, CH.dbd.CH or C.tbd.C, by reaction of 3-(3-pyridyl)-1-propionaldehyde with a compound of formula III,
- MZAr.sup.1 III
- wherein M represents Li, Na, K or MgHal where Hal represents Cl, Br or I, Z represents CH.sub.2 S, CH.dbd.CH or C.tbd.C and Ar.sup.1 is as defined in claim 1;
- (c) preparation of a compound of formula I, wherein X represents CH.sub.2 S, CH.sub.2 O or (CH.sub.2).sub.2, by reaction of 3-(2-oxiranylethyl)pyridine either with a compound of formula IV,
- MYAr.sup.1 IV
- or with a compound of formula VII,
- HYAr.sup.1 VII
- wherein Y represents O, S or CH.sub.2, M is as hereinbefore defined and Ar.sup.1 is as defined in claim 1;
- (d) preparation of a compound of formula I, wherein X represents CH.sub.2 S, CH.sub.2 O or (CH.sub.2).sub.2, by reaction of a compound of formula V, ##STR135## wherein M is as defined above, with a compound of formula VI, ##STR136## wherein Y is as defined above and Ar.sup.1 is as defined in claim 1; (e) preparation of a compound of formula I, wherein X represents CH.sub.2 S, CH.sub.2 O or (CH.sub.2).sub.2, by reaction of .alpha.-(chloromethyl)-3-pyridinepropanol either with a compound of formula IV,
- MYAr.sup.1 IV
- or with a compound of formula VII,
- HYAr.sup.1 VII
- wherein Y and M are as defined above and Ar.sup.1 is as defined in claim 1;
- (f) preparation of a compound of formula I, wherein X represents CH.sub.2 O or CH.sub.2 S, by reaction of a compound of formula IV or VII, as defined above, with a suitably protected and activated derivative of 4-(3-pyridyl)-1,2-butanediol;
- (g) preparation of a compound of formula I, wherein X is as defined in claim 1 and Ar.sup.1 represents an --Ar.sup.3 --Ar.sup.4 group in which Ar.sup.3 represents naphthylene or phenylene optionally substituted by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms) and Ar.sup.4 represents pyridyl, thiazinyl or phenyl which latter group is optionally substituted by one or more substituents selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19, SO.sub.2 NR.sup.17 R.sup.18 by reaction of a compound of formula VIII, ##STR137## wherein X and Ar.sup.3 are as defined above, with an aryl halide of formula XX
- Ar.sup.4 Hal XX
- wherein Hal represents triflate, Cl, Br or I and Ar.sup.4 is as defined above;
- (h) preparation of a compound of formula I wherein X is C.tbd.C by reaction between a compound of formula X,
- QAr.sup.1 X
- wherein Q represents Br, I or triflate and Ar.sup.1 is as defined in claim 1, with 5-(3-pyridyl)pent-1-yn-3-ol;
- (i) preparation of a compound of formula I, wherein X is as defined in claim 1 and Ar.sup.1 represents an --Ar.sup.3 --Ar.sup.4 group in which Ar.sup.3 and Ar.sup.4 are as defined above, by reaction of a compound of formula XI, ##STR138## wherein Hal represents Cl, Br, I or triflate and X and Ar.sup.3 are as defined above, with an arylboronic acid of formula XXI,
- Ar.sup.4 B(OH).sub.2 XXI
- wherein Ar.sup.4 is as defined above;
- (j) reduction of a compound of formula XII, ##STR139## wherein W represents CH.dbd.CH or C.tbd.C and X and Ar.sup.1 are as defined in claim 1, by reduction with a suitable reducing agent;
- (k) preparation of a compound of formula I, wherein X is CH.dbd.CH, by reaction of a phosphonium salt of formula XIII, ##STR140## wherein R is an aryl group, X.sup.- is chloride, bromide or iodide and Ar.sup.1 is as defined in claim 1, with a suitably protected derivative of 2-hydroxy-4-(3-pyridyl)butyraldehyde,
- or reaction of a compound of formula XXII, ##STR141## wherein R represents C.sub.1-6 alkyl or aryl and Ar.sup.1 is as defined in claim 1, with a suitably protected derivative of 2-hydroxy-4-(3-pyridyl)butyraldehyde; (1) preparation of a compound of formula I, wherein X is (CH.sub.2).sub.2 O or (CH.sub.2).sub.2 S, by reaction between a compound of formula VII, as defined above, and an optionally protected and suitably activated derivative of 5-(3-pyridyl)-1,3-pentanediol;
- (m) preparation of a compound of formula I, wherein X is CH.sub.2 CH.sub.2, by reduction of a corresponding compound of formula I wherein X is C.tbd.C;
- (n) preparation of a compound of formula I, wherein X is CH.sub.2 CH.sub.2, by reduction of a corresponding compound of formula I wherein X is CH.dbd.CH;
- (o) preparation of a compound of formula I, wherein X is trans-CH.dbd.CH, by reduction of a corresponding compound of formula I wherein X is C.tbd.C;
- (p) preparation of a compound of formula I, wherein X is cis-CH.dbd.CH, by reduction of a corresponding compound of formula I wherein X is C.tbd.C;
- (q) preparation of a compound of formula I, wherein X is CH.dbd.CH, by reaction of a compound of formula IX, as defined above, with 5-(3-pyridyl)-1-penten-3-ol;
- (r) preparation of a compound of formula I, wherein X is as defined in claim 1 and Ar.sup.1 represents an --Ar.sup.3 --Ar.sup.6 group in which Ar.sup.3 is as defined above and Ar.sup.6 represents a C.sub.7-9 alkylphenyl group which is optionally substituted by one or more substituents selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19, by reaction between a compound of formula XI, as defined above, and a compound of formula XXV,
- UAr.sup.6 XXV
- wherein U represents a C.sub.2-3 alkylenyl group and Ar.sup.6 is as defined;
- (s) reduction of a compound of formula XXVI, ##STR142## wherein X and Ar.sup.1 are as defined in claim 1 and W is as defined above;
- (t) preparation of a compound of formula I, wherein Ar.sup.1 represents naphthyl or phenyl substituted by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), or by phenyl or C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18, from a corresponding compound of formula I including a group convertible to a halo, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, alkyl, fluoroalkyl, nitro, OR.sup.3, C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 or SO.sub.2 NR.sup.17 R.sup.18 group by functional group interconversion;
- wherein any functional group present may be protected before reaction occurs and deprotected to give the compounds of formula I.
- 7. A compound of formula II ##STR143## or of formula XIV, ##STR144## wherein X.sup.a represents (CH.sub.2).sub.n S or (CH.sub.2).sub.n O or C.sub.2 alkylene, Ar.sup.1 is indanyl, naphthyl or phenyl, which latter two groups may be substituted by one or more substituents selected from the group consisting of chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 OR.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, pyridyl, thiazinyl, phenyl and C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituents selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18 ; wherein m is an integer of 1-3; R1, R2 and R3 independently represent H, C.sub.1-10 alkyl optionally substituted by one or more fluorine atoms, C.sub.7-9 alkylphenyl or phenyl, which latter group is optionally substituted by hydroxy; and R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 independently represent H, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or phenyl; and
- X is (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene, wherein n represents 1 or 2;
- in which any alkyl group present may be interrupted by one or more oxygen atoms;
- provided that when X represents CH.sub.2 CH.sub.2, Ar.sup.1 may not represent phenyl or phenyl substituted with one or more substituents OR.sup.1 in which R.sup.1 represents C.sub.1-10 alkyl.
- 8. A compound of formula XII, ##STR145## wherein W represents CH.dbd.CH or C.tbd.C, Ar.sup.1 is indanyl, naphthyl or phenyl, which latter two groups may be substituted by one or more substituents selected from the group consisting of chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, pyridyl, thiazinyl, phenyl and C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituents selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18, wherein m is an integer of 1-3; R1, R2 and R3 independently represent H, C.sub.1-10 alkyl optionally substituted by one or more fluorine atoms, C.sub.7-9 alkylphenyl or phenyl, which latter group is optionally substituted by hydroxy; and R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 independently represent H, C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or phenyl; and
- X is (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene, wherein n represents 1 or 2;
- in which any alkyl group present may be interrupted by one or more oxygen atoms;
- provided that when X represents CH.sub.2 CH.sub.2, Ar.sup.1 may not represent phenyl or phenyl substituted with one or more substituents OR.sup.1 in which R.sup.1 represents C.sub.1-10 alkyl.
- 9. A compound of formula I ##STR146## wherein: X represents (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene;
- n represents 1 or 2;
- Ar.sup.1 represents optionally substituted naphthyl or phenyl further including a substituent selected from amino, O(CH.sub.2).sub.m CO(O)R.sup.22 and CH(OH)R.sup.2 or Ar.sup.1 represents naphthyl or phenyl substituted with at least one group including phenyl or C.sub.7-9 alkylphenyl further including a substituent selected from CH(OH)R.sup.4 and CH.sub.2 Hal, wherein R.sup.22 represents C.sub.1-6 alkyl, Hal represents halogen;
- m represents an integer 1 to 3;
- R.sup.2 represents H, C.sub.1-10 alkyl optionally substituted by one or more fluorine atoms, C.sub.7-9 alkylphenyl or phenyl, which latter group is optionally substituted by hydroxy;
- R.sup.4 represent C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or phenyl;
- in which any alkyl group present may be interrupted by one or more oxygen atoms;
- provided that when X represents CH.sub.2 CH.sub.2, Ar.sup.1 may not represent phenyl or phenyl substituted with one or more substituents OR.sup.1, in which R.sup.1 represents C.sub.1-10 alkyl;
- or a pharmaceutically acceptable derivative thereof.
- 10. A pharmaceutical formulation including a compound of formula I as defined in claim 2, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 11. A method of treatment of a reversible obstructive airways disease which comprises administering a therapeutically effective amount of a compound of formula I as defined in claim 2 or a pharmaceutically acceptable derivative thereof to a person suffering from, or susceptible to, such a disease.
- 12. A method as claimed in claim 11, wherein the disease is asthma.
- 13. 4-(3-pyridyl)-1,2-butanediol.
- 14. (2R) 4-(3-pyridyl)-1,2-butanediol.
Priority Claims (3)
Number |
Date |
Country |
Kind |
9524920 |
Dec 1995 |
GBX |
|
9609403 |
May 1996 |
GBX |
|
9622412 |
Oct 1996 |
GBX |
|
Parent Case Info
This application is a 371 of PCT/SE96/01595, filed Dec. 4, 1996.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/SE96/01595 |
12/4/1996 |
|
|
3/3/1997 |
3/3/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/20815 |
6/12/1997 |
|
|
Foreign Referenced Citations (5)
Number |
Date |
Country |
0 264 114 A1 |
Apr 1988 |
EPX |
0 267 439 |
May 1988 |
EPX |
0 267 439 A2 |
May 1988 |
EPX |
0 391 624 |
Oct 1990 |
EPX |
9012006 |
Oct 1990 |
WOX |